Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trials
European Child & Adolescent Psychiatry · 2025
DOI: 10.1007/s00787-025-02681-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Child & Adolescent Psychiatry, 2025. Verfasst von Joan Busner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Signant Health, Blue Bell, PA, USA. joan.busner@signanthealth.com. Hauptthemen laut MEDLINE: Schizophrenia, Psychiatric Status Rating Scales, Antipsychotic Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Do the shortened Positive and Negative Syndrome Scale (PANSS) (Kay et al., J Clin Psychiatry 58:538–546, 1987) versions recently developed from a National Institute of Mental Health (NIMH) pediatric dataset continue to perform well in a third independent randomized double-blind clinical trial of adolescents with schizophrenia? Secondary analysis of the double-blind, placebo-controlled aripiprazole pivotal trial data ( N = 302) found that the 10-item (and 20-item) PANSS versions on which we have previously reported (Findling et al., J Am Acad Child Adolesc Psychiatry, https://doi.org/10.1016/j.jaac.2022.07.864 , 2023) continued to provide high reliability, strong convergent correlation with expected measures, and treatment effects that equaled those found in the 30-item adult PANSS. Our shortened PANSS, derived originally from the randomized non-placebo controlled NIMH Treatment of Early Onset Schizophrenia Spectrum study (TEOSS) (Sikich et al., Am J Psychiatry 165(11):1420–1431, 2008), and independently replicated in both the placebo-controlled paliperidone pivotal trial for adolescents with schizophrenia (Youngstrom et al., PsyArxiv, https://doi.org/10.31234/osf.io/zb695 , 2023), and now the placebo-controlled aripiprazole pivotal trial for adolescents with schizophrenia, has again performed as well as the full 30 item adult-patient derived PANSS. The findings suggest it is possible to reduce the PANSS interview by 2 thirds, thus reducing burden on families and pediatric patients as well as administration and training costs, while maintaining high reliability, validity, and sensitivity to treatment equal to that of the 30-item version.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Signant Health, Blue Bell, PA, USA. joan.busner@signanthealth.com.
- Virginia Commonwealth University School of Medicine, Richmond, VA, USA. joan.busner@signanthealth.com.
- Nationwide Children's Hospital and The Ohio State University, Helping Give Away Psychological Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Signant Health, McLean, VA, USA.
- George Washington University School of Medicine, Washington, DC, USA.
Zitieren
APA
Busner, J., Youngstrom, E. A., Langfus, J. A., Daniel, D. G., & Findling, R. L. (2025). Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trials. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-025-02681-1
Vancouver
Busner J, Youngstrom EA, Langfus JA, Daniel DG, Findling RL. Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trials. European Child & Adolescent Psychiatry. 2025. doi:10.1007/s00787-025-02681-1
BibTeX
@article{Busner2025,
author = {Busner, Joan and Youngstrom, Eric A and Langfus, Joshua A and Daniel, David G and Findling, Robert L},
title = {Replicating and extending the reliability, criterion validity, and treatment sensitivity of the shortened PANSS for pediatric trials},
journal = {European Child & Adolescent Psychiatry},
year = {2025},
doi = {10.1007/s00787-025-02681-1}
}
EUVIMED